NanoViricides (NNVC) AI Stock Analysis

• Market Cap: $24.62M
• Dividend Yield: N/A
• Average Volume (3M): 143.34K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.49
• Revenue Growth: N/A
• EPS Growth: 32.92%
• Country: US
• Employees: 7
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.14
• Shares Outstanding: 21,595,000
• 10 Day Avg. Volume: 199,739
• 30 Day Avg. Volume: 143,335
• PEG Ratio: 0.22
• Price to Book (P/B): 2.82
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.48
• Enterprise Value/Market Cap: -209.22K
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 15.88M
• Enterprise Value/Ebitda: 667.80K
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -0.47
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $1.00 ▼(-11.50% Downside)
• Action: Reiterated Date: 03/12/26
• Date: Action: Reiterated 03/12/26

The score is primarily held down by weak financial performance (no revenue, sustained losses, and consistent cash burn with likely ongoing funding needs). Technical indicators provide a modest offset via improving short-term momentum, but valuation remains constrained by negative earnings and no dividend support.

Positive Factors

Proprietary broad-spectrum antiviral platform

The proprietary nanoviricide platform is a durable strategic asset: a platform that can be applied to multiple viruses increases long-term optionality, attracts partners for co-development/licensing, and supports a scalable R&D roadmap that can drive future product opportunities beyond a single asset.

Near-zero leverage on balance sheet

Minimal debt materially reduces solvency and interest-rate risk, giving management flexibility to prioritize R&D and clinical work without immediate fixed-cost pressures. This structural strength improves run-rate resilience and lowers the chance of bankruptcy in prolonged development cycles.

Platform enables partner/licensing pathways

Because the business is platform-centric, the most durable commercial routes include licensing, milestones, and co-development deals. These non‑product revenue paths can provide non-dilutive capital, de‑risk programs via partners, and create recurring revenue streams once agreements are in place.

Negative Factors

No revenue and sustained net losses

Lack of product revenue leaves the company entirely dependent on financing rather than operational cash generation. Persistent net losses indicate limited operating leverage and no near-term pathway to profitability, increasing execution risk and lengthening the timeline before self-sustaining operations.

Consistent negative operating and free cash flow

Negative operating and free cash flow translate reported losses into real cash burn, creating ongoing funding needs. Structurally, this forces reliance on capital markets or partners for financing, which can delay programs, dilute shareholders, and constrain long-term strategic choices.

Declining equity base and dilution risk

A shrinking equity base reflects cumulative losses and prior financings, reducing the balance-sheet cushion available for setbacks. This structural deterioration increases the probability of future equity raises and dilution, and limits the company’s ability to absorb clinical or regulatory setbacks without partner support.

NanoViricides Business Overview & Revenue Model

Company Description

NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.

How the Company Makes Money

NanoViricides does not have a sustained, product-based commercial revenue stream because its drug candidates have not been approved for sale. As a result, the company’s funding has primarily come from capital markets financing—raising cash through the issuance of equity and equity-linked securities (e.g., common stock offerings and/or warrants) to investors to fund ongoing R&D, manufacturing scale-up work, and clinical development. Potential future ways the company would be expected to generate revenue (such as licensing its technology, entering co-development or commercialization partnerships, receiving milestone payments/royalties, or selling approved antiviral products) are not available as realized, recurring revenue streams based on publicly known outcomes to date; therefore, specific partner-driven revenues, milestone/royalty receipts, or product sales are null.

NanoViricides Financial Statement Overview

Summary

Financials reflect an early-stage biotech with no revenue, persistent sizable net losses, and ongoing operating/free-cash-flow burn. The low-debt balance sheet helps limit solvency risk, but equity has declined meaningfully over time, implying continued funding/dilution risk.

Income Statement

NNVC reports no revenue across the annual periods provided, which leaves the business fully dependent on funding rather than commercial execution. Losses are persistent and sizable, with net losses staying deeply negative each year (and extremely large in the latest TTM (Trailing-Twelve-Months) dataset), indicating weak operating leverage and limited visibility to near-term profitability. A modest positive is that annual losses have not accelerated dramatically from 2022–2025, but overall earnings quality remains very weak given the lack of revenue and ongoing operating losses.

Balance Sheet

The balance sheet shows essentially no leverage (debt is near-zero and debt-to-equity is minimal), which reduces solvency risk and provides flexibility. However, equity has trended down meaningfully over time (from about $29.9M in 2021 to about $7.5M in 2025 annual), reflecting cumulative losses and potential dilution risk. Returns on equity are consistently negative, highlighting that the capital base is not generating profits.

Cash Flow

Cash generation is consistently negative, with operating cash flow and free cash flow both outflows each year, implying ongoing cash burn. Free cash flow is roughly in line with net losses (free cash flow to net income is near 1.0), which suggests reported losses broadly translate into real cash usage rather than being purely non-cash. A key weakness is the lack of evidence of improving cash burn trajectory in the annual data (free cash flow growth is mixed and often negative), raising ongoing funding needs.

Breakdown	TTM	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-324.27K	0.00	0.00	-747.53K	0.00	0.00
EBITDA	-7.71M	-8.72M	-7.49M	-7.84M	-7.38M	-8.04M
Net Income	-8.32M	-9.47M	-8.29M	-8.59M	-8.11M	-8.82M
Balance Sheet
Total Assets	12.27T	8.82M	12.82M	16.90M	23.49M	30.26M
Cash, Cash Equivalents and Short-Term Investments	5.15T	1.56M	4.80M	8.15M	14.07M	20.52M
Total Debt	0.00	0.00	0.00	0.00	94.79K	95.31K
Total Liabilities	1.20T	1.31M	1.36M	2.03M	412.84K	351.15K
Stockholders Equity	11.07T	7.52M	11.46M	14.87M	23.08M	29.91M
Cash Flow
Free Cash Flow	-3.73T	-8.54M	-6.47M	-5.82M	-6.22M	-8.45M
Operating Cash Flow	-3.64T	-8.48M	-6.32M	-5.67M	-5.89M	-8.21M
Investing Cash Flow	-94.52K	-56.96K	-156.56K	-151.71K	-324.35K	-238.76K
Financing Cash Flow	8.62M	5.30M	3.12M	-94.79K	-234.72K	15.26M

NanoViricides Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.13
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NNVC, the sentiment is Positive. The current price of 1.13 is above the 20-day moving average (MA) of 1.03, above the 50-day MA of 1.06, and below the 200-day MA of 1.35, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 59.37 is Neutral, neither overbought nor oversold. The STOCH value of 69.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NNVC.

NanoViricides Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SABS	57 Neutral	$200.75M	5.44	-21.16%	―	-92.42%	62.37%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ENLV	49 Neutral	$256.37M	-2.84	-62.91%	―	―	46.09%
NNVC	45 Neutral	$24.62M	-2.53	-94.03%	―	―	32.92%
MBRX	45 Neutral	$10.11M	-0.19	―	―	―	79.31%
AKTX	42 Neutral	$6.75M	―	-68.21%	―	―	―